William Ho
2021 - IN8BIO
In 2021, William Ho earned a total compensation of $2.3M as President and Chief Executive Officer at IN8BIO, a 58% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $281,250 |
|---|---|
| Option Awards | $1,564,227 |
| Salary | $446,212 |
| Total | $2,291,689 |
Ho received $1.6M in option awards, accounting for 68% of the total pay in 2021.
Ho also received $281.3K in non-equity incentive plan and $446.2K in salary.
Rankings
In 2021, William Ho's compensation ranked 5,495th out of 12,415 executives tracked by ExecPay. In other words, Ho earned more than 55.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,495 out of 12,415 | 56th |
Division Manufacturing | 2,323 out of 5,505 | 58th |
Major group Chemicals And Allied Products | 1,010 out of 2,375 | 58th |
Industry group Drugs | 900 out of 2,096 | 57th |
Industry Biological Products, Except Diagnostic Substances | 219 out of 449 | 51st |
Source: SEC filing on April 22, 2022.
Ho's colleagues
We found two more compensation records of executives who worked with William Ho at IN8BIO in 2021.
News
RAPT Therapeutics CEO Brian Wong's 2023 pay jumps 26% to $6.6M
April 5, 2024
RAPT Therapeutics CEO Brian Wong's 2022 pay jumps 84% to $5.2M
April 7, 2023
IN8BIO CEO William Ho's 2021 pay jumps 51% to $2.3M
April 22, 2022
RAPT Therapeutics CEO Brian Wong's 2021 pay falls 21% to $2.8M
April 11, 2022
RAPT Therapeutics CEO Brian Wong's 2020 pay jumps 86% to $3.6M
April 15, 2021
RAPT Therapeutics CFO Rodney Young receives $2.3M in 2019
April 29, 2020